



## J. B. Chemicals & Pharmaceuticals Limited

Regd. Office : Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road, Worli, Mumbai 400 030.

Phone: 022-24822222 / 24930918 Fax : 022 – 2493 0534 / 2493 9633

CIN : L24390MH1976PLC019380 Website: www.jbcpl.com E-mail : secretarial@jbcpl.com

---

### Press Release

**BSE Scrip Code: 506943**

**NSE Symbol: JBCHEPHARM**

Mumbai, August 5, 2014:

### J.B. Chemicals reports robust bottom-line growth

### Unaudited Financial Results for Q 1- 2014-15

J.B. Chemicals & Pharmaceuticals Ltd. (JBCPL) today announced its standalone unaudited financial results for the quarter ended on June 30, 2014. The company posted good performance during the quarter. The highlights of Y-o-Y results are as under:

| (Rs. in crores)                                                                                     |               |               |
|-----------------------------------------------------------------------------------------------------|---------------|---------------|
| Particulars                                                                                         | Q1-2014-15    | Q1-2013-14    |
| Net Sales                                                                                           | <b>256.71</b> | <b>229.17</b> |
| Other Operating income                                                                              | 5.89          | 6.06          |
| Other Income                                                                                        | 1.74          | 1.51          |
| Total Revenue                                                                                       | 264.34        | 236.74        |
| Profit from ordinary activities after finance cost but before exchange fluctuation translation loss | 38.87         | 32.93         |
| Profit from ordinary activities before tax                                                          | <b>42.55</b>  | <b>27.49</b>  |
| Profit from ordinary activities after tax                                                           | 31.79         | 20.32         |
| EPS (Rs.) (FV 2)                                                                                    | <b>3.75</b>   | <b>2.40</b>   |

The net sales for the quarter at Rs. 256.71 crores were 12% higher against net sales in the corresponding quarter in the previous year. However, this is strictly not comparable Y-o-Y due to commencement of sales and distribution in Russia & CIS countries by the wholly owned subsidiary company during the quarter. The profit from operations [before other income (Rs.1.74 crores), finance cost (Rs. 1.33 crores) and depreciation (Rs.9.90 crores)] at Rs. 48.35 crores was 20% higher against the same quarter in the previous year.

The domestic formulations business at sales of Rs. 104 crores registered growth of 19%. The company is fully focused on this business which has significant value potential. The contrast media products sales in domestic market registered growth of 17%.

The formulations exports at Rs. 119 crores registered growth of 9% during the quarter. The exports of formulations to Rest of the world markets at Rs. 84 crores registered growth of 19% in Rupee terms. The company continues to grow in this market particularly US keeping in view its potential.

The net sales for the quarter are strictly not comparable due to the company's wholly owned subsidiary in Dubai commencing sales and distribution of the products in Russia-CIS countries during the quarter. This subsidiary will also undertake some of the expenses, and hence this arrangement is not expected to have significant impact on the company. Due to this arrangement, the company's export revenue for Russia-CIS market at Rs. 15 crores for the quarter is not comparable with the same quarter in the previous year.

The API business with sales for the quarter at Rs. 24 crores registered growth of 5%.

## **NEW CAPEX**

In order to tap opportunities, the company has undertaken expansion programme to create additional capacity for tablets, liquid, ointments, vials, eye drops, lozenges and Diclofenac API plant. The company plans to invest about Rs. 140 crores in this new capacity and related infrastructure in the next 12-18 months. This capital expenditure will be met out of internal accruals.

## **About JBCPL:**

JBCPL, one of India's leading pharmaceutical companies, manufactures & markets a diverse range of pharmaceutical formulations, herbal remedies and APIs. JBCPL exports to many countries worldwide with a strong presence in Russia, Ukraine, CIS countries and South Africa. The Company continues to invest in growing its share in the regulated markets in USA, Europe and Australia. JBCPL has a strong R & D and regulatory set-up for development of new drug delivery system and formulations, filing of DMFs and ANDAs. Its State-of-the-Art manufacturing facilities are approved by health authorities of regulated markets.

For more information on JBCPL visit our website at [www.jbcpl.com](http://www.jbcpl.com). For more details, you may contact:

M.C. Mehta  
Company Secretary- General Manager  
J. B. Chemicals & Pharmaceuticals Ltd.  
91 22 24822311

-- x --

### *Forward Looking Statements:*

*This Press Release may contain Forward Looking Statements regarding future events and future performance of J.B. Chemicals & Pharmaceuticals Ltd. that involve risks and uncertainties that could cause actual results to differ materially from those that may be indicated by such statements.*